The Immunoglobulin National Society (IgNS) is pleased to share information about the launch of the Distinction in Immunoglobulin Therapy, a new recognition from ACHC for pharmacies that deliver immunoglobulin therapy in alignment with advanced clinical, operational, and safety expectations.
Developed in collaboration with IgNS, this distinction recognizes organizations that demonstrate advanced clinical, operational, and safety practices in the delivery of immunoglobulin across care settings. It is grounded in the IgNS Standards of Practice, a comprehensive, evidence-based framework for the safe and effective use of immunoglobulin therapy.
This distinction evaluates:
• Collaboration across the care team
• Management of safety and tolerability
• Processes that support consistent, appropriate immunoglobulin therapy
This recognition builds on ACHC’s pharmacy accreditation programs and provides organizations with a way to demonstrate quality, credibility, and leadership in immunoglobulin therapy.